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license (http://creativecommons.org/Abstract For over 40 years, the left internal thoracic artery has been used as the gold stan-
dard for myocardial revascularization and anastomosis over the left anterior descending artery
due to its excellent patency rates. However, the right internal thoracic artery behaves in the
same manner as the left, also having excellent long-term patency. Hence, no patient should be
deprived of the benefits of total arterial revascularization allowed by the bilateral use of both
internal thoracic arteries.
ª 2016 Hellenic Cardiological Society. Publishing services by Elsevier B.V. This is an open ac-
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Half a million patients per year worldwide are estimated to
undergo coronary artery bypass grafting (CABG)1 CABG re-
mains a superior option for revascularization compared to
percutaneous coronary intervention (PCI) in cases of severe
coronary artery disease (CAD)2,3 owing to its major advan-
tage of no need for repeat intervention.3 Accordingly, an
appropriate graft selection is a sine qua non to minimize
mortality and reintervention. Currently, the left internal
thoracic artery to the left anterior descending coronary. Papakonstantinou, MD, 12
Athens, Greece. Tel.:
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cal Society. Publishing services by
licenses/by-nc-nd/4.0/).artery (LITA or LIMA-LAD) graft is unanimously considered the
gold standard of conduits.4 Conduit selection for the grafting
of the other coronary arteries varies. Provided that half of
the saphenous vein (SV) grafts are patent without significant
stenoses at 10 years,5 some surgeons have fueled an interest
in total arterial revascularization using one or both internal
thoracic arteries (BITA or BIMA) and other arterial conduits
such as the radial artery (RA) or the right gastroepiploic ar-
tery (GEA). Given the numerous advantages of BITA grafting
and arterial conduits in terms of survival and extended
patency rates, patients referred for surgery should not be
denied the benefits of total arterial revascularization.6
2. Indications-contraindications
Every eligible patient should receive total arterial revas-
cularization, the cornerstone of which is BITA grafting.
Patients with a body mass index (BMI) of over 35, diabetesElsevier B.V. This is an open access article under the CC BY-NC-ND
Total arterial revascularization 153or severe airway disease or who are undergoing radio-
therapy or immunosuppression are only relatively contra-
indicated for BITA use.7 If more conduits are required, the
RA can be prepared at the same time as the LITA, and its
harvesting is associated with favorable early outcomes.4
Prior to harvesting, a modified Allen test is performed. If
a hyperemic response to the previous ischemic hand is
noticed within 5 s, the collateral ulnar circulation is
adequate. Restoration of the blood circulation to the
ischemic hand later than 10 s after the ulnar release ex-
cludes the RA from being used.8 Duplex examination and
pulse oximetry can also be used to preoperatively evaluate
the RA and ulnar artery. Moreover, the RA should be avoi-
ded when cardiac catheterization has been recently pre-
ceded by injuring the vessel and when the RA might be used
for future fistulae in patients who are receiving or who are
likely to receive dialysis.7 RAs less than 2 mm in diameter
are also avoided due to the possibility of vasospasm.9
Finally, the extent of stenosis of the target coronary
vessel may also constitute a contraindication for arterial
conduit use due to competitive flow. Hence, stenoses of
less than 70% in the left coronary bed and less than 90% in a
dominant right coronary artery should prevent the use of an
arterial graft.7
3. Graft patencies
High occlusion rates of vein grafts due to atherosclerosis of
12%, 25% and 50% within 1 year, 5 years and 12 years after
CABG, respectively,10,11 result in an increased need for
repeat revascularization. Therefore, three percent of pa-
tients who have received vein grafts undergo a repeat
revascularization procedure within 5 years, 10% within 10
years and 25% within 20 years.12 Veins appear to be 2.6
times more prone to dysfunction than arteries.13 Conse-
quently, grafts with superior patency rates are sought
either to prolong intervals to repeat revascularization or to
prevent the need for repeat operations.1
As many as 80% of ITA conduits have been shown to be
free from failure in the third decade after CABG.7 RITA
patency is 96% at 5 years and 81% after 10 years, levels that
are comparable to LITA patency of 98% and 95%, respec-
tively.14 Tatoulis et al. reported similar patency between
RITAs and LITAs when grafted to the same target vessel of
96.5% vs. 94.5%, respectively, when grafted to the LAD and
90.5% vs. 88.5%, respectively, when grafted to the
circumflex artery.15 Several angiographic studies from 6.7
to 12 years following surgery have reported that RITA graft
patency ranges from 86% to 97% at levels similar to LITA
patency rates.16e19
Conversely, the patency rates of the RA range from 83%
to 93% at one to seven years postoperatively,20 thus
demonstrating a superior patency of the RA compared to
the SV.21,22 A meta-analysis has compared 419 RA to 412
SV grafts at follow-up times beyond three years. The
complete occlusion rate of the RA was 6.7% vs. 17.2% for
the SV grafts. RA graft failure was also significantly
lower compared to SV grafts (9.6% vs. 18.8%). The graft
patency of RAs of 88.6% was superior to that of the SVs of
75.8%. Similar findings have been reported by a recent
single-institution study involving 1,851 patients showing asuperiority of the RA compared to the SV in terms of graft
patency and graft failure,23 as well as a meta-analysis by
Athanasiou and colleagues that observed better mid-term
patency (1e5 years) for RA grafts.24
For gastroepiploic artery grafts, the 5-year patency
rates are similar to those of the SV grafts of 62% and 86% in
two large studies.25,26 However, skeletonized gastro-
epiploic arteries appear to have superior outcomes when
compared to SV grafts.27
4. Morbidity-mortality
Total arterial revascularization using BITA is also advanta-
geous in terms of long-term survival, as well as reoperation
and the need for angioplasty.28e34 A clear benefit is seen in
the first postoperative decade in cases using BIMA, and its
advantage becomes even more apparent during the second
postoperative decade.35,36 A retrospective study by Lytle29
has demonstrated a survival advantage associated with the
use of BITA. Survival in the BITA group was 94%, 84% and 67%
vs. 92%, 79% and 64% in the LITA group at 5, 10, and 15 years
postoperatively, respectively (p<0.001). Another study by
the same authors28 showed a survival benefit of greater
than 10% for BITA grafting at 20 postoperative years, except
for in patients with a small body surface area and for those
of advanced age, in whom BITA was inferior to LITA in terms
of survival. Survival in the BITA group was 89%, 81%, 67% and
50% vs. 87%, 78%, 58% and 37% in the LITA group at 7, 10, 15
and 20 years, respectively (p<0.0001). Similar results were
observed by Stevens and colleagues,30 who reported sur-
vival benefit for BIMA on the order of 5% at 10 years (88% for
the single-graft group versus 93% for the BIMA group;
p<0.001). Grau et al.37 compared 1459 BIMA and 4854 LIMA
patients. Although the in-hospital and 30-day mortality
rates were not significantly different between the two
groups (0.8 vs. 1.1%, respectively; PZ 0.47), BIMA grafting
was superior to LIMA with regards to long-term survival.
This survival benefit was once again demonstrated to be
more in favor of the BIMA group throughout the 17-year
follow-up period (96 versus 91% at 5 years, 89 versus 79%
at 10 years and 79% versus 61% at 15 years). Interestingly,
the late mortality risk was almost twice as high in patients
undergoing on-pump LIMA grafting compared to those with
off-pump BIMA grafting.37 Taggart et al.34 performed a
meta-analysis of seven observational studies comparing
11,269 LIMA patients to 4,693 BIMA patients in 2001. A
significant average survival benefit of 8 years was observed
throughout the follow-up for the BIMA group. Similar results
showing a statistically significant survival advantage with
BIMA throughout a 7.6-year follow-up period even in dia-
betic patients was reported by another larger meta-analysis
including 27 studies that compared 19,277 BIMA to 59,786
LIMA patients. Long-term mortality was also significantly
reduced among patients receiving BIMA grafting.38 More-
over, statistically significantly lower mortality and the need
for percutaneous coronary intervention and decreased
myocardial infarctions after BITA use at 20 postoperative
years were reported by Rankin et al.39 More postoperative
deaths were also reported for the LITA group according to a
retrospective study by Konstanty-Kalandyk40 including 147
patients with coronary artery disease and diabetes (3.67 for
154 N.A. Papakonstantinou, N.G. Baikoussisthe LITA vs. 2.63% for the BITA). Diabetic patients who
underwent BITA harvesting had an increased 10-year sur-
vival rate41 and a lower perioperative mortality rate
compared to the LITA group.42 Stevens et al.43 reported
lower mortality and total hospital mortality rates (0 vs.
0.5%, 0.9 vs 2.6%) when comparing BITA to LITA in diabetic
patients. Thirty-day mortality was also lower in the BITA
than in the LITA group for diabetic patients (3.1 vs. 4.7%),
according to Gansera et al.44
As far as morbidity is concerned, the BITA procedures
also appear to be superior to the LITA ones. Although no
benefit is observed during the first 4 years after the oper-
ation, a clear benefit is gained from the use of BITA after 15
years, as a 9% decrease is reported for angina recurrence.45
BITA is also associated with an additional 7 years of
freedom from reoperation as a result of better graft
patency rates, as reported by Endo and colleagues.32 The
same authors also observed an advantage of BITA use in
terms of 10-year freedom from adverse events only when
the ejection fraction was >40%.41 According to Berreklouw
and colleagues,33 49.4% of LIMA patients either died or
experienced angina recurrence, new myocardial infarction
and underwent CABG again at 13 years compared to 33.3%
of the BIMA patients (pZ0.0004). Similarly, BIMA use was
also an independent predictor of greater freedom from
recurrent angina, late myocardial infarction and adverse
cardiac events in a study by Pick and colleagues.46 Grau
et al. reported no significant differences with regard to
perioperative complications and postoperative length of
stay between BITA and LITA use, although more BIMA pa-
tients required blood transfusions.37 Momin et al.47 further
reported that sternal wound infection risk was not
increased when BITA was used in insulin-dependent dia-
betic patients, similar to the results of Svensson et al.,48
who concluded that the use of the right internal thoracic
artery is not related to a higher incidence of deep sternal
wound infection in diabetic or non-diabetic patients.
However, reoperation for bleeding is significantly more
likely to occur in BIMA than in LIMA patients (2.9% vs. 0.6%),
and sternal revision is also significantly more likely for BIMA
patients (1.4% vs. 0.6%), according to Gansera et al.445. Objections to the use of BITA. Does
skeletonization solve the problem?
Most patients with three-vessel CAD can receive total
arterial revascularization.49 However, its use is not wide-
spread. The most cited disadvantages in the use of BITA are
deep sternal wound infection (DSWI) and a higher risk of
death. DSWI is perceived to be the result of sternal hypo-
perfusion due to the bilateral use of IMA.37 Diabetes has
been recognized as an additional independent risk factor for
sternal wound infection.50 Resternotomy for bleeding is
another strong risk factor for DSWI, as is peripheral arte-
riopathy.6 Savage et al.42 observed that diabetic patients
are more prone to DSWI when BITA is used and when they
are insulin dependent and obese (BMI >35) and have pe-
ripheral arteriopathy. Similarly, Konstanty-Kalandyk et al.40
reported that older and more obese diabetic patients were
at increased risk of DSWI. According to Zhang et al.,51 dia-
betic patients were 3.47 times more prone to DSWI for every10 years of age and 6.80 times more prone to DSWI with BMIs
of greater than 30. However, the bilateral use of IMAs in
diabetic patients did not increase the risk of DSWI compared
to unilateral use. According to De Paulis et al.,6 28% of the
diabetic patients with chronic obstructive pulmonary dis-
ease, peripheral arteriopathy and a BMI>30 experienced
DSWI, whereas only 2.3% of those without the aforemen-
tioned risk factors had DSWI. De Paulis et al.6 reported that
sternal infection was clearly more common in BIMA patients
than in LIMA patients (1.1% vs. 4.2%; P Z 0.004). However,
when skeletonized ITA grafts were used, BITA use was no
longer an independent predictor of DSWI.6
Skeletonization of the ITA, which was first used by
Keeley in 1987,52 refers the untouched mobilization of the
artery and its accompanying veins and surrounding tis-
sues.53 In this way, the artery branches are ligated close to
the artery so that collateral circulation to the sternum is
maintained.54 Thus, bilateral skeletonized IMAs minimize
sternal infection risk at levels comparable to those for LIMA
patients, particularly in diabetic patients.55,56 Although
some cardiac surgeons suspect that skeletonization dam-
ages the endothelium, a review of the literature by Atha-
nasiou et al.57 revealed neither damage of the ITA nor a
worsening of its patency when skeletonized ITAs were
compared to pedicled ITAs. Ali et al., upon examining 17
papers, reported excellent patency rates for both pedicled
and skeletonized arteries that exceeded 95% at three
postoperative years.58 Therefore, we can conclude that
patients can gain the full benefits from BITA grafting and
maintain sternal, collateral circulation if skeletonized
pedicles are used.6
6. Conclusions
Most patients with multivessel CAD can successfully receive
total arterial revascularization. Total arterial revasculari-
zation is associated with higher graft patency rates,
excellent long-term survival rates, fewer harvest site
complications, lower CAD progression and reduced adverse
cardiac events resulting in reoperation.1,7,53 Patients
referred to surgery should in no way be denied the advan-
tages of total arterial revascularization. BIMA grafting can
be safely performed,1 and skeletonization of both ITAs
minimizes sternal infection complications, thus increasing
the number of candidates for BITA grafting by including
many diabetic patients.6 However, patients with many risk
factors for wound complications should not receive BITA
grafting. Furthermore, postoperative bleeding requiring
resternotomy in BITA patients should also be avoided, as
reexploration is a potent risk factor for sternal infection.6
Consequently, total arterial revascularization with the use
of bilateral ITAs should be the method of choice for
revascularization procedures, as it has numerous benefits
that cannot be ignored.4,6,38
7. Acknowledgments/Disclosures
No grants or funding were received. The authors had full
control of the design of the study, methods used, outcome
parameters and results, analysis of data and production of
the written report. No conflicts of interest were declared.
Total arterial revascularization 155References
1. Parissis H, Soo AW, Al-Alao B. Is there any further advantage of
using more than one internal mammary artery? Literature re-
view and analysis. Asian CardiovascThorac Ann. 2013;21:
101e113.
2. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery
bypass graft surgery versus percutaneous coronary intervention
in patients with three-vessel disease and left main coronary
disease: 5-year follow-up of the randomised, clinical SYNTAX
trial. Lancet. 2013;381:629e638.
3. Cao C, Manganas C, Bannon P, Vallely M, Yan TD. Drug-eluting
stents versus coronary artery bypass graft surgery in left main
coronary artery disease: a meta-analysis of early outcomes
from randomized and nonrandomized studies. J Thor-
acCardiovascSurg. 2013;145:738e747.
4. Lytle BW. Bilateral internal thoracic artery grafting. Ann Car-
diothoracSurg. 2013;2:485e492.
5. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft
disease: pathogenesis, predisposition, and prevention. Circu-
lation. 1998;97:916e931.
6. De Paulis R, de Notaris S, Scaffa R, et al. The effect of bilateral
internal thoracic artery harvesting on superficial and deep
sternal infection: the role of skeletonization. J Thor-
acCardiovascSurg. 2005;129:536e543.
7. Buxton BF, Hayward PA. The art of arterial revascular-
izationdtotal arterial revascularization in patients with triple
vessel coronary artery disease. Ann CardiothoracSurg. 2013;2:
543e551.
8. Conklin LD, Ferguson ER, Reardon MJ. The technical aspects of
radial artery harvesting. Tex Heart Inst J. 2001;28:129e131.
9. Blitz A, Osterday RM, Brodman RF. Harvesting the radial artery.
Ann CardiothoracSurg. 2013;2:533e542.
10. FitzGibbon GM, Kafka HP, Leach AJ, Burton JR. Interventions
for coronary stenosisda Canadian experience of 30 revolu-
tionary years. Can J Cardiol. 1996;12:893e900.
11. Bourassa MG. Long-term vein graft patency. CurrOpinCardiol.
1994;9:685e691.
12. Cohn LH. Cardiac surgery in the adult. New York; London:
McGraw-Hill Medical; 2008.
13. Magee MJ, Alexander JH, Hafley G, Ferguson Jr TB, Gibson CM,
Harrington RA. Coronary artery bypass graft failure after on-
pump and off-pump coronary artery bypass: findings from
PREVENT IV. Ann ThoracSurg. 2008;85:494e499.
14. Tatoulis J, Buxton BF, Fuller JA. Patencies of 2127 arterial to
coronary conduits over 15 years. Ann ThoracSurg. 2004;77:
93e101.
15. Tatoulis J, Buxton BF, Fuller JA. The right internal thoracic
artery: the forgotten conduite5,766 patients and 991 angio-
grams. Ann ThoracSurg. 2011;92, 9-15; discussion 15e17.
16. Chow MS, Sim E, Orszulak TA, Schaff HV. Patency of internal
thoracic artery grafts: comparison of right versus left and
importance of vessel grafted. Circulation. 1994;90(suppl II):
129e132.
17. Dion R, Glineur D, Derouck D, et al. Long-term clinical and
angiographic follow-up of sequential internal thoracic artery
grafting. Eur J CardiothoracSurg. 2000;17:407e414.
18. Gansera B, Schmidtler F, Angelis I, Kiask T, Kemkes BM,
Botzenhardt F. Patency of internal thoracic artery compared to
vein graftsdpostoperative angiographic findings in 1189
symptomatic patients in 12 years. ThoracCardiovascSurg.
2007;55:412e417.
19. Shah PJ, Durairaj M, Gordon I, et al. Factors affecting patency
of internal thoracic artery graft: clinical and angiographic
study in 1434 symptomatic patients operated between 1982
and 2002. Eur J CardiothoracSurg. 2004;26:118e124.20. Ngaage DL, Cowen ME, Griffin S, Guvendik L, Cale AR. The
impact of symptom severity on cardiac reoperative risk: early
referral and reoperation is warranted. Eur J CardiothoracSurg.
2007;32:623e628.
21. Cao C, Manganas C, Horton M, et al. Angiographic outcomes of
radial artery versus saphenous vein in coronary artery bypass
graft surgery: a meta-analysis of randomized controlled trials.
J ThoracCardiovascSurg. 2013;146:255e261.
22. Schwann TA, Engoren M, Bonnell M, Clancy C, Habib RH.
Comparison of late coronary artery bypass graft survival ef-
fects of radial artery versus saphenous vein grafting in
male and female patients. Ann ThoracSurg. 2012;94:
1485e1491.
23. Tranbaugh RF, Dimitrova KR, Friedmann P, et al. Coronary ar-
tery bypass grafting using the radial artery: clinical outcomes,
patency, and need for reintervention. Circulation. 2012;126:
S170eS175.
24. Athanasiou T, Saso S, Rao C, et al. Radial artery versus
saphenous vein conduits for coronary artery bypass surgery:
forty years of competitionewhich conduit offers better
patency? A systematic review and meta-analysis. Eur J Car-
diothoracSurg. 2011;40:208e220.
25. Suma H, Tanabe H, Takahashi A, et al. Twenty years experi-
ence with the gastroepiploic artery graft for CABG. Circula-
tion. 2007;116:I188eI191.
26. Takahashi K, Daitoku K, Nakata S, Oikawa S, Minakawa M,
Kondo N. Early and mid-term outcome of anastomosis of gas-
troepiploic artery to left coronary artery. Ann ThoracSurg.
2004;78:2033e2036. discussion 2036.
27. Suzuki T, Asai T, Matsubayashi K, et al. In off-pump surgery,
skeletonized gastroepiploic artery is superior to saphenous
vein in patients with bilateral internal thoracic arterial grafts.
Ann ThoracSurg. 2011;91:1159e1164.
28. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD,
Cosgrove DM. The effect of bilateral internal thoracic artery
grafting on survival during 20 postoperative years. Ann Thor-
acSurg. 2004;78:2005e2014.
29. Lytle BW, Blackstone EH, Loop FD, et al. Two internal thoracic
arteries are better than one. J ThoracCardiovascSurg. 1999;
117:855e872.
30. Stevens LM, Carrier M, Perrault LP, et al. Single versus bilateral
internal thoracic artery grafts with concomitant saphenous
vein grafts for multivessel coronary artery bypass grafting:
effects on mortality and event-free survival. J Thor-
acCardiovascSurg. 2004;127:1408e1415.
31. Kurlansky PA, Traad EA, Dorman MJ, Galbut DL, Zucker M,
Ebra G. Thirty-year follow-up defines survival benefit for sec-
ond internal mammary artery in propensity-matched groups.
Ann ThoracSurg. 2010;90:101e108.
32. Endo M, Nishida H, Tomizawa Y, Kasanuki H. Benefit of bilateral
IMA grafts over single IMA graft for multiple coronary artery
bypass grafting. Circulation. 2001;104:2164e2170.
33. Berreklouw E, Rademakers PPC, Koster JM, van Leur L, van der
Wielen BJW, Westers P. Better ischemic event-free survival
after two internal thoracic artery grafts: 13 years of follow-up.
Ann Thorac Surg. 2001;72:1535e1541.
34. Taggart DP, D’Amico R, Altman DG. Effect of arterial revascu-
larization on survival: a systematic review of studies comparing
bilateral and single internal mammary arteries. Lancet. 2001;
358:870e875.
35. Avgerinos DV, Charitakis K. Hybrid coronary revascularization:
present and future. HJC. 2015;56:193e196.
36. Doumas A, Christoforidis T, Iakovou I, Mosialos L, Bobotis G,
Karatzas N. Incidence of reversible defect seen on myocardial
perfusion scintigraphy using dipyridamole pharmacologic test
early after primary percutaneous coronary intervention: how
156 N.A. Papakonstantinou, N.G. Baikoussissafe is it to perform this protocol? Hellenic J Cardiol. 2014;55:
492e498.
37. Grau JB, Ferrari G, Mak AW, et al. Propensity matched analysis
of bilateral internal mammary artery versus single left internal
mammary artery grafting at 17-year follow-up: validation of a
contemporary surgical experience. Eur J Cardiothorac Surg.
2012;41:770e776.
38. Weiss AJ, Zhao S, Tian DH, Taggart DP, Yan TD. A meta-analysis
comparing bilateral internal mammary artery with left internal
mammary artery for coronary artery bypass grafting. Ann
Cardiothorac Surg. 2013;2:390e400.
39. Rankin JS, Tuttle RH, Wechsler AS, Teichmann TL, Glower DD,
Califf RM. Techniques and benefits of multiple internal
thoracic artery bypass at 20 years of follow-up. Ann Thor-
acSurg. 2007;83:1008e1014.
40. Konstanty-Kalandyk J, Piatek J, Rudzinski P, Wrobel K,
Bartus K, Sadowski J. Clinical outcome of arterial myocardial
revascularization using bilateral internal thoracic arteries in
diabetic patients: a single centre experience. Interact Car-
diovascThorac Surg. 2012;15:979e983.
41. Endo M, Tomizawa Y, Nishida H. Bilateral versus unilateral in-
ternal thoracic revascularization in patients with diabetes.
Circulation. 2003;108:1343e1349.
42. Savage EB, Grab JD, O’Brien SM, et al. Use of bilateral internal
thoracic arteries in diabetic patients increases deep sternal
wound infection. Ann ThoracSurg. 2007;83:1002e1006.
43. Stevens LM, Carrier M, Perrault LP, et al. Influence of diabetes
and bilateral internal thoracic artery grafts on long-term
outcome for multivessel coronary artery bypass grafting. Eur
J CardiothoracSurg. 2005;27:281e288.
44. Gansera B, Schmidtler F, Gillrath G, et al. Does bilateral ITA
grafting increase perioperative complications? Outcome
of 4462 patients with bilateral versus 4204 patients with single
ITA bypass. Eur J CardiothoracSurg. 2006;30:318e323.
45. Naunheim KS, Barner HB, Fiore AC. 1990: results of internal
thoracic artery grafting over 15 years: single versus double
grafts. 1992 update. Ann ThoracSurg. 1992;53:716e718.
46. Pick AW, Orszulak TA, Anderson BJ, Schaff HV. Single versus
bilateral internal mammary artery grafts: 10-year outcome
analysis. Ann ThoracSurg. 1997;64:599e605.
47. Momin AU, Deshpande R, Potts J, et al. Incidence of sternal
infection in diabetic patients undergoing bilateral internalthoracic artery grafting. Ann ThoracSurg. 2005;80:
1765e1772.
48. Svensson LG, Mumtaz MA, Blackstone EH, et al. Does use of a
right internal thoracic artery increase deep wound infection
and risk after previous use of a left internal thoracic artery? J
ThoracCardiovascSurg. 2006;131:609e613.
49. Itagaki S, Cavallaro P, Adams DH, Chikwe J. Bilateral internal
mammary artery grafts, mortality and morbidity: an analysis of
1 526 360 coronary bypass operations. Heart. 2013;99:
849e853.
50. Filsoufi F, Rahmanian PB, Castillo JG, Mechanick JI, Sharma SK,
Adams DH. Diabetes is not a risk factor for hospital mortality
following contemporary coronary artery bypass grafting.
Interact CardioVascThoracSurg. 2007;6:753e758.
51. Zhang X, Wu Z, Peng X, et al. Prognosis of diabetic patients
undergoing coronary artery bypass surgery compared with
nondiabetics: a systematic review and meta-analysis. J Car-
diothoracVascAnesth. 2011;25:288e298.
52. Keeley SB. The skeletonized internal mammary artery. Ann
ThoracSurg. 1987;44:324e325.
53. Hu X, Zhao Q. Skeletonized internal thoracic artery harvest
improves prognosis in high-risk population after coronary ar-
tery bypass surgery for good quality grafts. Ann Thorac Surg.
2011 Jul;92:48e58.
54. Berdajs D, Zu¨nd G, Turina MI, Genoni M. Blood supply of the
sternum and its importance in internal thoracic artery har-
vesting. Ann ThoracSurg. 2006;81:2155e2159.
55. Kamiya H, Akhyari P, Martens A, Karck M, Haverich A,
Lichtenberg A. Sternal microcirculation after skeletonized
versus pedicled harvesting of the internal thoracic artery:
a randomized study. J ThoracCardiovascSurg. 2008;135:
32e37.
56. Deo SV, Shah IK, Dunlay SM, et al. Bilateral internal thoracic
artery harvest and deep sternal wound infection in diabetic
patients. Ann ThoracSurg. 2013;95:862e869.
57. Athanasiou T, Crossman MC, Asimakopoulos G, et al. Should the
internal thoracic artery be skeletonized? Ann Thorac Surg.
2004;77:2238e2246.
58. Ali E, Saso S, Ashrafian H, Athanasiou T. Does a skeletonized or
pedicled left internal thoracic artery give the best graft
patency? Interact CardiovascThoracSurg. 2010;10:97e104.
